Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm, Single Center Phase 2 Study of RC48-ADC (IV) in Combination With Gemcitabine(Intravesical) in High Risk NMIBC Subjects (BCG Naïve or BCG Unresponsive) That Expresses HER2 (IHC 1+ and Greater)

NCT05943379 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.

NCT NCT05943379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05943379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm, Single Center Phase 2 Study of RC48-ADC (IV) in Combination With Gemcitabine(Intravesical) in High Risk NMIBC Subjects (BCG Naïve or BCG Unresponsive) That Expresses HER2 (IHC 1+ and Greater)
Lead sponsor
RemeGen Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
June 8, 2023
Completion date
December 1, 2026
Enrollment
85 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nmibc